Parking...
SAN CARLOS, Calif.--(BW HealthWire)--May 30, 2001-- Neugenesis Corporation announced U.S. Patent Office allowance of its application entitled ``Combinatorial Metabolic Libraries''. This new patent significantly expands the Neugenesis proprietary position for generation and discovery of new, biologically useful, molecules. The patent covers methods for creating panels of cell cultures expressing natural and synthetic variants of multi-gene metabolic pathways.
``This new patent supports our previously issued US patents 5,643,745 and 5,683,899 in the area of combinatorial biology'' said Neugenesis President and CEO, W. Dorsey Stuart, Ph.D., author of all three patents. ``Coupled with our 14 other issued patents, this allowance puts Neugenesis at the cutting edge of directed evolution technologies for gene pathways and single gene biotherapeutic products.'' Stuart said.
Neugenesis Corporation is a privately held biotechnology company focused on generation of diversity of single gene products and multi-gene pathways. The Company holds a strong intellectual property position in the areas of in vivo gene diversification and in vivo combinatorial biology. Both platforms are synergistically coupled to protein expression for direct readout of altered properties of newly created proteins.
The company knows of no other technology that is able to create combinatorial arrays of multimeric protein complexes that have undergone target-directed evolution. These arrays are ideal for the expression and rapid identification of altered heterologous proteins made of non-identical subunits. Human growth hormone and monoclonal antibodies are examples of this class of biopharmaceutical proteins. The arrays are also ideal for expressing variants of entire metabolic pathways and for drug discovery of metabolites synthesized serially by metabolic pathway enzymes. Polyketides represent one example of this class of metabolites.
Statements in this press release that are not strictly historical are ``forward-looking'' statements, which involve a high degree of risk and uncertainty. These include statements related to the discovery of novel biotherapeutic molecules and new synthetic pathways, both of which are prospective. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements.
For further information, please visit the Neugenesis web site at neugenesis.com or contact Dr. W. Dorsey Stuart at 650/508-9671... |
